Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 59 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Parkinsons Disease With Dementia Clear all
Completed No phase listed Observational Accepts healthy volunteers

Measuring Cortisol Levels in Persons With Parkinson's (PD)

NCT02727270
View directory record Official record
Conditions
Parkinson Disease, Huntington Disease
Interventions
No Intervention - Observational Study
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 8, 2026, 5:31 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Community Outreach for Palliative Engagement -- Parkinson Disease

NCT05222386
View directory record Official record
Conditions
Parkinson Disease Dementia, Parkinson Disease, Parkinson's Disease and Parkinsonism, Lewy Body Parkinsonism, Dementia With Lewy Bodies, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multiple System Atrophy, Vascular Parkinsonism
Interventions
Parkinson Disease Standard Care, Online Community-Supported Palliative Care
Other
Lead sponsor
University of Rochester
Other
Eligibility
40 Years and older
Enrollment
632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 8, 2026, 5:31 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Moving Yourself in Space and Time: MYSTIC

NCT07697664
View directory record Official record
Conditions
Parkinson's Disease (PD), Alzheimer's Disease (AD) and Related Disorders, Older Adults (60 - 85 Years Old)
Interventions
Complex Rhythmic Movement Sequences (CRMS) Sessions
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 79 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 8, 2026, 5:31 AM EDT
Completed Not applicable Interventional Results available

Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

NCT00294554
View directory record Official record
Conditions
Parkinson's Disease, Cognitive Impairment, Dementia
Interventions
Memantine, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 8, 2026, 5:31 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Adaptango Performance PRocess for Older Adults Community reHabilitation

NCT07824128
View directory record Official record
Conditions
Parkinson Disease, Mild Cognitive Impairment, Old Age; Dementia
Interventions
Adaptango Performance Process (APP) program
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 8, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

NCT03713957
View directory record Official record
Conditions
Parkinson Disease
Interventions
GRF6021, Placebo
Drug · Other
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Englewood, Colorado • Doral, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 8, 2026, 5:31 AM EDT
Completed Phase 3 Interventional

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

NCT00056524
View directory record Official record
Conditions
Alzheimer's Disease, Stroke, Parkinson's Disease, Traumatic Brain Injury
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
39
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 8, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

NCT02910102
View directory record Official record
Conditions
Alzheimer's Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
Interventions
RVT-101 35 mg, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 89 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Phoenix, Arizona • Simi Valley, California • Temecula, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 8, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

NCT02708186
View directory record Official record
Conditions
Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Parkinson's Disease Dementia
Interventions
Nelotanserin, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 8, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nilotinib in Cognitively Impaired Parkinson Disease Patients 001

NCT02281474
View directory record Official record
Conditions
Parkinson's Disease, Parkinson's Disease Dementia, Diffuse Lewy Body Disease
Interventions
Nilotinib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
40 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 8, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

NCT00623103
View directory record Official record
Conditions
Parkinson's Disease Dementia
Interventions
Rivastigmine capsule, Rivastigmine transdermal patch
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years to 85 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Reseda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2011 · Synced Oct 8, 2026, 5:31 AM EDT
Completed Not applicable Interventional

Gamma Sensory Flicker for Parkinson's Disease Patients With Freezing of Gait

NCT06295458
View directory record Official record
Conditions
Gait Disorders, Neurologic, Parkinson Disease
Interventions
David Delight Plus Device, Sham Therapy
Device · Other
Lead sponsor
Emory University
Other
Eligibility
50 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 8, 2026, 5:31 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain

NCT06445465
View directory record Official record
Conditions
Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies, Multisystem Atrophy
Interventions
[18F]MNI-1216
Drug
Lead sponsor
Invicro
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 8, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems

NCT00988117
View directory record Official record
Conditions
Parkinsons Disease With Dementia, Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems
Interventions
Rivastigmine Patch 9.5 cm2
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Oct 8, 2026, 5:31 AM EDT
Terminated Not applicable Interventional

Neurocognitive Effects of Bilateral STN Versus GPi DBS in Parkinson's Disease Patients With MCI

NCT01870518
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment, Dementia
Interventions
Bilateral GPi DBS, Bilateral STN DBS
Device
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 8, 2026, 5:31 AM EDT
Completed No phase listed Observational

Diagnosis and Natural History Study of Patients With Neurological Conditions

NCT00001549
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Movement Disorder, Multiple System Atrophy, Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 8, 2026, 5:31 AM EDT
Completed Not applicable Interventional

Music Therapy to Prevent Hospital-acquired Delirium in Parkinson's Disease and Dementia With Lewy Bodies

NCT06063161
View directory record Official record
Conditions
Parkinson Disease, Dementia, Lewy Body, Delirium
Interventions
Music therapy intervention, Standard Care (in control arm)
Behavioral · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 8, 2026, 5:31 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biofluid Research on Age-Related or Inherited Neurodegeneration

NCT07798700
View directory record Official record
Conditions
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Fronto-temporal Lobar Dementia, Dementia With Lewy Bodies (DLB), Cortical Basal Syndrome (CBS), Alzheimer's Disease (AD), Progressive Supranuclear Palsy(PSP), Parkinson's Disease (PD), Parkinson's Disease Dementia (PDD), Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), Posterior Cortical Atrophy (PCA), Primary Lateral Sclerosis (PLS), Primary Muscular Atrophy (PMA)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2070
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 8, 2026, 5:31 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Telehealth in Lewy Body Dementia

NCT05014971
View directory record Official record
Conditions
Lewy Body Dementia With Behavioral Disturbance, Lewy Body Parkinson Disease, Lewy Body Disease
Interventions
Tele-neurohub
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 8, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

NCT05104463
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia
Interventions
CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
Drug
Lead sponsor
CuraSen Therapeutics, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Scottsdale, Arizona • Lafayette, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 8, 2026, 5:31 AM EDT
Terminated Phase 2 Interventional Results available

ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)

NCT04831281
View directory record Official record
Conditions
Parkinson Disease Dementia, Dementia With Lewy Bodies
Interventions
ATH-1017, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
40 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Boca Raton, Florida • West Palm Beach, Florida • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 8, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

NCT01461109
View directory record Official record
Conditions
Parkinson Disease, Alzheimer Disease
Interventions
[18F] CFPyPB
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 8, 2026, 5:31 AM EDT
Not listed Phase 1 Interventional

A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

NCT06309147
View directory record Official record
Conditions
Parkinson Disease
Interventions
BMS-9894923
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 8, 2026, 5:31 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

NCT05395624
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Interventions
18F-OP-801
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
San Francisco, California • Stanford, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 8, 2026, 5:31 AM EDT